PURPOSE: Medulloblastoma is a highly lethal disease when it recurs. Very few patients survive with conventional treatment. This study evaluated the use of high-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue (ASCR) in patients with recurrent medulloblastoma. METHODS: Chemotherapy consisted of carboplatin 500 mg/m2 (or area under the curve = 7 mg/mL x min via Calvert formula) on days -8, -7, and -6; and thiotepa 300 mg/m2 and etoposide 250 mg/m2 on days -5, -4, and -3; followed by ASCR on day 0. In addition to the study-prescribed therapy, 21 patients received other treatment: neurosurgical resection in seven, conventional chemotherapy in 17, and external-beam irradiation in 11 cases. RESULTS: Twenty-three patients with recurrent medulloblastoma, aged two to 44 years (median, 13 years) at ASCR, were treated. Three patients died of treatment-related toxicities within 21 days of ASCR; multiorgan system failure in two, and Aspergillus infection with venoocclusive disease in one. Seven of 23 patients (30%) are event-free survivors at a median of 54 months post-ASCR (range, 24 to 78 months). Kaplan-Meier estimates of event-free (EFS) and overall survival are 34% +/- 10% and 46% +/- 11%, respectively, at 36 months post-ASCR. CONCLUSION: This strategy may provide long-term survival for some patients with recurrent medulloblastoma.
PURPOSE:Medulloblastoma is a highly lethal disease when it recurs. Very few patients survive with conventional treatment. This study evaluated the use of high-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue (ASCR) in patients with recurrent medulloblastoma. METHODS: Chemotherapy consisted of carboplatin 500 mg/m2 (or area under the curve = 7 mg/mL x min via Calvert formula) on days -8, -7, and -6; and thiotepa 300 mg/m2 and etoposide 250 mg/m2 on days -5, -4, and -3; followed by ASCR on day 0. In addition to the study-prescribed therapy, 21 patients received other treatment: neurosurgical resection in seven, conventional chemotherapy in 17, and external-beam irradiation in 11 cases. RESULTS: Twenty-three patients with recurrent medulloblastoma, aged two to 44 years (median, 13 years) at ASCR, were treated. Three patients died of treatment-related toxicities within 21 days of ASCR; multiorgan system failure in two, and Aspergillus infection with venoocclusive disease in one. Seven of 23 patients (30%) are event-free survivors at a median of 54 months post-ASCR (range, 24 to 78 months). Kaplan-Meier estimates of event-free (EFS) and overall survival are 34% +/- 10% and 46% +/- 11%, respectively, at 36 months post-ASCR. CONCLUSION: This strategy may provide long-term survival for some patients with recurrent medulloblastoma.
Authors: Ira J Dunkel; Sharon L Gardner; James H Garvin; Stewart Goldman; Weiji Shi; Jonathan L Finlay Journal: Neuro Oncol Date: 2010-01-11 Impact factor: 12.300
Authors: Ulrich Herrlinger; A Steinbrecher; J Rieger; P Hau; R-D Kortmann; R Meyermann; M Schabet; M Bamberg; J Dichgans; U Bogdahn; M Weller Journal: J Neurol Date: 2005-02-23 Impact factor: 4.849
Authors: Sridharan Gururangan; Jeanne Krauser; Melody A Watral; Tim Driscoll; Nicole Larrier; David A Reardon; Jeremy N Rich; Jennifer A Quinn; James J Vredenburgh; Annick Desjardins; Roger E McLendon; Herbert Fuchs; Joanne Kurtzberg; Henry S Friedman Journal: Neuro Oncol Date: 2008-08-28 Impact factor: 12.300
Authors: C Altshuler; K Haley; G Dhall; L Vasquez; S L Gardner; J Stanek; J L Finlay Journal: Bone Marrow Transplant Date: 2016-03-07 Impact factor: 5.483
Authors: Diana S Osorio; Ira J Dunkel; Kelly Ann Cervone; Rakesh K Goyal; K M Steve Lo; Jonathan L Finlay; Sharon L Gardner Journal: Pediatr Blood Cancer Date: 2017-09-14 Impact factor: 3.167
Authors: Irene Slavc; Elisabeth Schuller; Jutta Falger; Mehmet Günes; Konrad Pillwein; Thomas Czech; Wolfgang Dietrich; Karl Rössler; Karin Dieckmann; Daniela Prayer; Johannes Hainfellner Journal: J Neurooncol Date: 2003-09 Impact factor: 4.130